rs121918387 — APOB ApoB-67 frameshift

Single-nucleotide deletion in APOB creating a truncated apolipoprotein B (ApoB-67) — carriers have dramatically reduced LDL and total cholesterol with strong cardiovascular protection, but face risk of hepatic steatosis and fat-soluble vitamin deficiency

See your personal result for APOB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ApoB-67 — When Too Little Cholesterol Becomes a Problem

Apolipoprotein B (ApoB) is the structural backbone of every VLDL and LDL particle11 VLDL and LDL particle
Very low-density lipoprotein (VLDL) is assembled in the liver and exports triglycerides to peripheral tissues; LDL is the remnant particle that delivers cholesterol to cells. Both require ApoB-100 as their obligate structural protein. Without functional ApoB, the liver cannot export triglycerides, and without efficient VLDL secretion, fat accumulates within hepatocytes. The rs121918387 variant introduces a single thymine deletion at coding position c.9200 that shifts the reading frame at codon 3,067 — producing a truncated protein, ApoB-67, containing approximately 3,040 amino acids instead of the normal 4,536. The result is a carrier phenotype unlike most genetic risk variants: dramatically low cholesterol that protects the heart, but at the cost of impaired hepatic lipid export and fat-soluble vitamin transport.

The Mechanism

Welty et al. 199122 Welty et al. 1991
Welty FK et al. A truncated species of apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia. J Clin Invest identified this variant in a large kindred and showed that seven of twelve children of the proband had hypobetalipoproteinemia. The truncated ApoB-67 protein is detectable in plasma within VLDL and LDL fractions, but at very low concentrations — consistent with impaired secretion and accelerated clearance. Unlike the full-length ApoB-100 particle which is cleared primarily through LDL receptors in the liver, truncated ApoB particles are cleared rapidly via megalin receptors33 cleared rapidly via megalin receptors
Megalin (LRP2) is a multi-ligand endocytic receptor expressed on kidney proximal tubular cells and other epithelia; it binds and internalizes truncated ApoB particles more efficiently than LDL receptors handle full-length ApoB-100 in renal proximal tubular cells, which further depletes circulating levels.

The liver consequence is the flip side: because VLDL secretion is impaired, the triglycerides that would normally be packaged and exported accumulate as intracellular lipid droplets. Four interconnected mechanisms drive liver injury in APOB-FHBL: intracellular triglyceride accumulation from failed VLDL export, endoplasmic reticulum stress from defective ApoB protein folding, oxidative damage from reactive oxygen species generated by excess lipid, and impaired autophagy of lipid-laden organelles.

The Evidence

The cardiovascular protection from APOB truncation mutations is substantial and well-replicated. Welty 202044 Welty 2020
Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol synthesized data from 12 case-control studies involving approximately 58,000 individuals and found that apoB truncation mutations were associated with a 72% reduction in coronary heart disease (OR 0.28, 95% CI 0.12–0.64; P=0.002). This mirrors the pharmacological effect of PCSK9 inhibitors, which lower LDL by similar magnitudes — supporting APOB truncation as a natural Mendelian randomization model for LDL reduction.

The hepatic risk, however, is real and common. A retrospective cohort study55 retrospective cohort study
Sürücü Kara et al. 2025. Clinical and biochemical spectrum of APOB-related hypobetalipoproteinemia: Insights from a retrospective cohort. J Clin Lipidol of 15 APOB-FHBL patients found hepatosteatosis on liver ultrasound in 73.3%, and elevated transaminases in 20–27%. Median LDL cholesterol was 25.7 mg/dL — dramatically below the normal range. Vitamin D insufficiency affected 66.7% of patients, and vitamin E deficiency 26.7%, consistent with reduced fat-soluble vitamin transport by apoB-containing lipoproteins.

Heterozygous carriers are usually mildly affected, but approximately 5–10% develop more severe nonalcoholic steatohepatitis66 nonalcoholic steatohepatitis
NASH: inflammation and fibrosis superimposed on fatty liver, driven by oxidative stress, lipotoxicity, and immune activation. In biallelic (homozygous) carriers, the clinical picture is substantially more severe: severe intestinal lipid malabsorption, profound fat-soluble vitamin deficiency, and risk of cirrhosis and hepatocellular carcinoma have all been documented.

Practical Actions

Heterozygous carriers of the ApoB-67 deletion should be proactively monitored for hepatic steatosis and fat-soluble vitamin status, since the very low LDL that defines this genotype can be falsely reassuring. Because ApoB-containing lipoproteins are the main carriers of vitamins A, D, E, and K through the bloodstream, impaired VLDL secretion reduces circulating levels of all four — regardless of dietary intake. Annual monitoring of serum 25-hydroxyvitamin D, vitamin E (alpha-tocopherol), and vitamin A (retinol) is warranted. Liver enzymes (ALT, AST, GGT) should be checked at least annually; if elevated or if steatosis is found on imaging, hepatology referral is appropriate. Fat restriction can reduce hepatic triglyceride accumulation, but should be balanced against the need for adequate fat-soluble vitamin absorption.

Interactions

APOB-FHBL interacts meaningfully with other APOB variants. Compound heterozygosity or homozygosity for APOB truncation alleles — as can occur when two carriers reproduce — produces a biallelic phenotype resembling abetalipoproteinemia, with severe fat malabsorption and progressive neurological deterioration from vitamin E deficiency. Related APOB truncation variants include rs5742904 (ApoB-31), rs267607000 (ApoB-46), and rs1801702 (ApoB-87). Carriers of multiple truncation alleles in trans have been reported with severe liver disease, retinal degeneration, and peripheral neuropathy.

The hepatic steatosis mechanism in APOB-FHBL is distinct from APOE-mediated dyslipidemia (rs429358, rs7412). APOE ε4 causes elevated LDL and remnant lipoproteins; APOB truncation causes failed VLDL export and intrahepatic fat trapping. The two mechanisms converge on liver disease risk but through opposite lipid-level phenotypes and require very different clinical responses.

Nutrient Interactions

vitamin E reduced_absorption
vitamin A reduced_absorption
vitamin D reduced_absorption
vitamin K reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

II Non-Carrier Normal

No ApoB-67 deletion — normal apolipoprotein B function

You do not carry the rs121918387 deletion. Your APOB gene produces full-length apolipoprotein B-100, enabling normal VLDL and LDL assembly and secretion. This is the universal baseline — the deletion allele occurs in fewer than 1 in a million individuals in gnomAD, making it one of the rarest pathogenic APOB variants catalogued. Your cholesterol transport, hepatic lipid export, and fat-soluble vitamin delivery through lipoproteins are unaffected by this variant.

DD ApoB-67 Homozygous Absent

Two copies of the ApoB-67 deletion — severe hypobetalipoproteinemia with fat malabsorption and neurological risk

Biallelic APOB truncation produces a clinical picture dominated by failure of lipid absorption at the intestinal level and failure of hepatic lipid export. Fat-soluble vitamins A, D, E, and K cannot be absorbed or delivered to tissues, causing progressive deficiency of all four. Without vitamin E, the peripheral nervous system degenerates progressively — beginning with loss of deep tendon reflexes, progressing to ataxia and sensory neuropathy. Retinal pigmentation abnormalities and impaired night vision follow from vitamin A deficiency. Vitamin K deficiency causes coagulopathy.

In GeneReviews (Burnett et al. 2021), biallelic APOB-FHBL patients require high-dose fat-soluble vitamin supplementation: vitamin E at 100–300 IU/kg/day, vitamin A at 100–400 IU/kg/day, vitamin D at 800–1,200 IU/day, and vitamin K at 5–35 mg/week. Without early treatment, neurological and ophthalmological complications are progressive and partially irreversible. Liver disease can advance to cirrhosis and hepatocellular carcinoma.

If this result appears in a WGS report, verify it orthogonally before acting — homozygous calls for ultra-rare variants are susceptible to technical artifacts including sample contamination and informatic misalignment.

DI ApoB-67 Carrier Carrier

One copy of the ApoB-67 deletion — low LDL with hepatic steatosis and vitamin deficiency risk

The ApoB-67 truncation prevents the liver from efficiently exporting triglycerides as VLDL particles. Triglycerides accumulate intracellularly, causing hepatic steatosis visible on liver ultrasound. In a 2025 cohort study of APOB-FHBL patients, 73.3% had hepatosteatosis detected by ultrasound, and liver enzyme elevations were present in 20–27%. Hepatocellular carcinoma has been reported in cases with progressive chronic liver disease, emphasizing the importance of monitoring over time.

Fat-soluble vitamins (A, D, E, K) are normally transported through the bloodstream packaged inside ApoB-containing lipoprotein particles. Reduced VLDL and LDL production impairs this delivery mechanism, causing deficiency states even with adequate dietary intake. Vitamin D insufficiency affected 66.7% and vitamin E deficiency 26.7% in the 2025 cohort — both at rates far exceeding the general population baseline.

The cardiovascular protection is genuine and substantial. A synthesis of 12 case-control studies found OR 0.28 (95% CI 0.12–0.64) for coronary heart disease — a 72% reduction. However, this protection does not extend to liver disease risk, which requires active monitoring independent of lipid levels.